Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Financings

Citius Pharmaceuticals, Inc.

Financings

RaiseDate
Registered direct offering of shares of common stock (or pre-funded warrants)
Closed: US$5M raised · US$0.985 a share · Warrants at US$0.86 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Commercial launch of LYMPHIR including milestone and regulatory payments, development of product candidates, and general corporate purposes
Apr 27, 2026
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants
Closed: US$6M raised · US$1.51 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, including milestone and regulatory payments, development of product candidates, and general corporate purposes
Oct 21, 2025
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying short-term warrants
Closed: US$6M raised · US$1.22 a share · Warrants at US$1 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, including milestone, regulatory and other payments, and general corporate purposes
Jun 12, 2025
Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof)
Announced: about US$2M · US$1.15 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR and general corporate purposes
Apr 1, 2025
Registered direct offering of shares of common stock and accompanying warrants
Announced: about US$3M · US$4.035 a share · Warrants at US$3.91 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: General corporate purposes, including pre-clinical and clinical development of product candidates, working capital and capital expenditures
Jan 8, 2025

Read by 6ix AI from the company's releases